Kymera weakness says a purchase opportunity, stifel

Stifel Analyst Alex Thompson repeats a purchase rating in Kymera therapeutics (Kymr) The partner Sanofi’s decision, including “Updates Slide,” (Cut off) Leader IRAK4 DEGRADER KT-474, coordinate with the next Gen KT-485 and Gilead with a new partnership dealDice) for a CDK2 molecular glue degrader. An update related to Iraq4 is “disappointed and eliminates potential catalysts”, Sanofi, waiting for KT-485 to the 1st stage next year and records a broader partnership analytics. In the Gilead deal, Kymera will receive advanced and options up to 85 m, today the news will look at any weakness of today’s news, the more pipeline and additional stages remain in reserve. Stifel has a purchase rating about Kymera shares from Kymera shares to $ 1.18 or 2.5%, 2.5% in morning trade.

Was first published Tort – Real-time mode, the last source for financial news moving in the market. Try it now >>

See the best shares recommended by analysts >>

Read more about kymr:

Refusal and DisclosureReport an issue